Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI AG 2020-03-01
Serie:International Journal of Molecular Sciences
Ämnen:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Länkar:https://www.mdpi.com/1422-0067/21/7/2275
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk